News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Novartis Pharma And Nippon Kayaku Revise Sales Agreement For Aredia
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
On December 16, Novartis Pharma and Nippon Kayaku (TSE: 4272) have agreed to revise their agreement concerning sales of antihypercalcemic agent "Aredia."
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Mergers & acquisitions
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
September 21, 2026
·
3 min read
·
Tristan Manalac
Obesity
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
September 21, 2026
·
1 min read
·
Tristan Manalac
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
·
2 min read
·
Annalee Armstrong
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
